Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir

Autor: Lúcia de Araújo Costa Beisl Noblat, Júnior André da Rosa, João Paulo Vilela Rodrigues, Ana de Lourdes Candolo Martinelli, Marysabel Pinto Telis Silveira, Lenyta Oliveira Gomes, Mariane D Ávila Vecchi, Silvana Gama Florencio Chachá, Marina Rodrigues Teixeira, Leonardo Régis Leira Pereira, Mareni Rocha Farias, Carine Raquel Blatt, Alberi Adolfo Feltrin, Jane Meire M. Carneiro

Publikováno v: Revista do Instituto de Medicina Tropical de São Paulo; Vol. 60 (2018); e29
Revista do Instituto de Medicina Tropical de São Paulo; v. 60 (2018); e29
Revista do Instituto de Medicina Tropical de São Paulo
Instituto de Medicina Tropical (IMT)
instacron:IMT
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Revista do Instituto de Medicina Tropical de São Paulo, Volume: 60, Article number: e29, Published: 28 JUN 2018
Revista do Instituto de Medicina Tropical de São Paulo, Vol 60, Iss 0 (2018)

In 2012, the first-generation protease inhibitors telaprevir (TVR) and boceprevir (BOC) were introduced in the Brazilian health system for treatment of chronic hepatitis C, after their approval by the National Committee for Health Technology Incorpor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::483ea6dd53865c31215b795f2459d7cd
https://www.revistas.usp.br/rimtsp/article/view/148079